The lifecycle of M. tuberculosis within the human host is marked by critical transition points between the major phases of infection: Initial infection, latent disease, active tuberculosis, and resolution with antibiotic therapy. Through observation of patients in each of these stages, we have some knowledge about host determinants that maintain each of these stages, such as the need for sufficient CD4 T cells, interferon gamma and tumor necrosis factor alpha in the control of latency. However, the vast majority of HIV negative TB patients do not have defined deficiencies in these immune factors and therefore the host determinants of the heterogeneous ability of TB patients to control M. tuberculosis infection, either in the context of initial infection after exposure, reactivation of latent infection, or relapse-free elimination of M. tuberculosis after antimicrobial therapy, are unknown. To address these knowledge gaps, we have assembled a set of patient cohorts to examine three interrelated host factors that we hypothesize may contribute to the heterogeneity in host control of M. tuberculosis during the transition from uninfected>LTBl and infected>cured. These factors are Mucosal Associated Invariant T (MAIT) cells, whole blood transcriptomic signatures, and stool microbiomic composition. We will initially examine these factors in two cohorts of TB patients: 1) Patients either resistant to initial infection or recently infected from a household contact, a comparison which will yield correlates of innate resistance to infection and 2) Patients undergoing therapy for active pulmonary tuberculosis, either with short course monotherapy or standard multidrug therapy, to determine correlates of clearance of replicating and persister M. tuberculosis. We anticipate that these studies will provide a set of quantitative molecular assays that will both expand our knowledge ofthe heterogeneity of host control of M. tuberculosis infection, and potentially supply biomarkers that will allow identification of patients resistant to infection, destined to reactivate from latency, or to relapse after antimicrobial therapy.

Public Health Relevance

This project will examine factors that determine the resistance of patients to different forms of infection by M. tuberculosis. These studies will clarify why some patients control this infection effectively, while some do not, and may provide biomarkers that will allow us to predict which patients will develop illness or respond to antibiotic therapy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI111143-01
Application #
8726599
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10065
Namasivayam, Sivaranjani; Maiga, Mamoudou; Yuan, Wuxing et al. (2017) Longitudinal profiling reveals a persistent intestinal dysbiosis triggered by conventional anti-tuberculosis therapy. Microbiome 5:71
Botella, Laure; Vaubourgeix, Julien; Livny, Jonathan et al. (2017) Depleting Mycobacterium tuberculosis of the transcription termination factor Rho causes pervasive transcription and rapid death. Nat Commun 8:14731
Salerno Jr, Stephen; Mehrmohamadi, Mahya; Liberti, Maria V et al. (2017) RRmix: A method for simultaneous batch effect correction and analysis of metabolomics data in the absence of internal standards. PLoS One 12:e0179530
Hartman, Travis E; Wang, Zhe; Jansen, Robert S et al. (2017) Metabolic Perspectives on Persistence. Microbiol Spectr 5:
Saito, Kohta; Warrier, Thulasi; Somersan-Karakaya, Selin et al. (2017) Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations. Proc Natl Acad Sci U S A 114:E4832-E4840
Eoh, Hyungjin; Wang, Zhe; Layre, Emilie et al. (2017) Metabolic anticipation in Mycobacterium tuberculosis. Nat Microbiol 2:17084
Wipperman, Matthew F; Fitzgerald, Daniel W; Juste, Marc Antoine Jean et al. (2017) Antibiotic treatment for Tuberculosis induces a profound dysbiosis of the microbiome that persists long after therapy is completed. Sci Rep 7:10767
Jansen, Robert S; Rhee, Kyu Y (2017) Emerging Approaches to Tuberculosis Drug Development: At Home in the Metabolome. Trends Pharmacol Sci 38:393-405
Nathan, Carl (2017) Kunkel Lecture: Fundamental immunodeficiency and its correction. J Exp Med 214:2175-2191
Hsu, Hao-Chi; Singh, Pradeep K; Fan, Hao et al. (2017) Structural Basis for the Species-Selective Binding of N,C-Capped Dipeptides to the Mycobacterium tuberculosis Proteasome. Biochemistry 56:324-333

Showing the most recent 10 out of 25 publications